COVID: J&J vaccine; viral load after vaccine
The formal study on safety and efficacy data were released for the single-dose Johnson & Johnson/Janssen Covid-19 vaccine (see covid vaccine J&J nejm2021 in dropbox, or DOI: 10.1056/NEJMoa2101544 ) Details: -- international, randomized, double-blind, placebo-controlled trial with 19,630 SARS-CoV-2 negative participants who received the J&J vaccine and 19,691 placebo recipients, from September 21, 2020 to January 22, 2021 -- this vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length SARS-CoV-2 spike protein -- median age 52 (67% 18-59yo, 34% >60yo), 45% female, BMI 27, 41% at least one coexisting condition, 59% white/20% Black/ indigenous South American/ Hispanic -- 41% from Latin America (Brazil 17%, Colombia 10%, rest from Argentina, Chile, Mexico, Peru); 15% South Africa; 44% US -- primary endpoints: vaccine efficacy against moderate to severe-critical...